Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities

Pancreatic cancer remains as one of the most aggressive types. In absence reliable biomarkers for its early detection and more effective therapeutic interventions, pancreatic is projected to become second leading cause death in Western world next decade. Therefore, it essential discover novel targets develop cancer-specific agents. To date, 45 monoclonal antibodies (mAbs) have been approved treatment patients with a wide range cancers; however, none has yet cancer. this comprehensive review, we discuss FDA anticancer mAb-based drugs, results preclinical studies clinical trials mAbs factors contributing poor response antibody therapy (e.g. tumour heterogeneity, desmoplastic stroma). MAb technology an excellent tool studying complex biology cancer, various forms antibody-based agents companion diagnostic tests selection who are likely benefit from such therapy. These should result approval routine use future.